GSK shrugs off generic threat to Advair; U.K. again rejects Roche's Tarceva for maintenance;

@FiercePharma: Can we foot the bill for pricey prostate-cancer meds? Article | Follow @FiercePharma

> Potential generic rivals to GlaxoSmithKline's $8 billion-a-year Advair treatment for asthma and smoker's cough can hope to capture only "a very small fraction" of its sales, the British drugmaker's research chief said. Report

> MannKind said it will pay $16 million to a unit of Merck & Co to settle a dispute related to the termination of an insulin supply agreement. Report

> Britain's health cost watchdog has again rejected Roche's Tarceva pill for long-term use in lung cancer patients because it is too costly for the benefit it offers. Report

> Diabetic patients with a vision-robbing eye condition who were treated with Roche's (ROG.VX) Lucentis had significant and sustained vision improvement compared with those who received a placebo, according to new trial data. Report

> Amgen (AMGN) sold $3 billion of bonds in the largest debt sale this month as borrowing costs for investment-grade companies fall to about the lowest this year. Report

> Pfizer is threatening U.K. pharmacies with legal action if they supply Teva Pharmaceutical's knockoff versions of the cholesterol drug Lipitor before a court fight between the companies is resolved. Report

> Danish drugmaker Novo Nordisk (NOVOb.CO) is applying for U.S. approval for use of its diabetes drug Victoza in combination with long-acting insulins. Report

> The generic drug metformin is a cost-effective way to help prevent Type 2 diabetes in people at high risk of developing the chronic condition, according to a new economic analysis. Report

> Merck has broadened its North American distribution and logistics deal with UPS to distribute pharmaceuticals internationally. Report

Biotech News

@FierceBiotech: Competition gets fierce for innovative science. Report | Follow @FierceBiotech 

@JohnCFierce: Chatted with Ian Tomlinson, worldwide business czar for GSK. Can't say I learned much new, though oncology, inflammation are a hot deal source. | Follow @JohnCFierce

Drug Delivery News

> Red-blooded delivery device gets by body's defenses. Report

> MEMS implant could target diabetic retinopathy. Article

> Nebraska nanoscientist returns to Mother Russia with $4.5M grant. Story

> Digna to use Flamel's drug-delivery technologies in three products. Article

> Pop goes the nanotube for targeted drug delivery. Item

> Defense Department interested in Impel's BBB-busting device. Report

Medical Device News

> Allegro enters agreement with schools for lung cancer testing platform. Story

> Live from BIO 2011: Polybatics looks to improve diagnostics through beads. Report

> InfraReDx raises $24.1M from equity offering. Article

> Medtronic's Infuse targeted in scientific journal. News

> Medtronic introduces mobile app for use with cardiac devices. Report

And Finally... Barry J. Marshall, the Australian scientist who won a Nobel Prize for identifying a cancer-causing stomach bacterium, plans to start a trial next year using the bug in a drinkable flu vaccine. Report

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.